Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. Show more

Location: 3891 Ranchero Drive, Ann Arbor, MI, 48108, United States | Website: https://www.esperion.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare


Market Cap

489.9M

52 Wk Range

$0.69 - $3.94

Previous Close

$2.43

Open

$2.44

Volume

7,268,891

Day Range

$2.40 - $2.58

Enterprise Value

706.1M

Cash

86.06M

Avg Qtr Burn

-31.08M

Insider Ownership

0.56%

Institutional Own.

50.55%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Nexlizet (bempedoic acid and ezetimibe) Details
Hypercholesterolemia, Atherosclerotic cardiovascular disease , Heterozygous familial hypercholesterolemia, Cardiovascular risk reduction

Approved

Quarterly sales

Nexletol (bempedoic acid) Details
Heterozygous familial hypercholesterolemia, Atherosclerotic cardiovascular disease , Hypercholesterolemia

Approved

Quarterly sales

Bempedoic acid Details
Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia

Phase 3

Initiation